SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Elan Corporation, plc (ELN)
An SI Board Since October 1996
Posts SubjectMarks Bans Symbol
10345 171 0 ELN
Emcee:  Harold Engstrom Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10245UPDATE 1-European regulators recommend Tysabri label update Thu Jan 21, 2010 2:sim1-1/21/2010
10244NEJM articles on MS drugs Fingolimod and Cladribine Published at www.nejm.org Jsim1-1/21/2010
10243Two MS Pills Show Promise Novartis, Merck drugs—effective in trials—could be bosim1-1/21/2010
10242finance.yahoo.comArthur Radley-1/11/2010
102414 more PML cases in November, but still under ratio for black box listing. (:<Arthur Radley-1/6/2010
10240Some bad news for ELN AZ pipe, and worse news for TTHI. From todays Goodbody Irifred hayes-12/15/2009
10239finance.yahoo.com Finally...some potential good news out of ELNs other project Arthur Radley112/4/2009
10238Finally, BIIB and ELN get their voice for TY efficacy balanced with risk... Thpgo-neil212/2/2009
10237Roy, My daughter participated in the Cladridine trials and the AEs were numerousArthur Radley-12/1/2009
10236DECEMBER 1, 2009 FDA Rejects Approval of MS Drug By NATASCHA DIVAC [WSJ] Germsim1-12/1/2009
10235I’m surprised no one here is talking about the FDA’s RTF letter for Cladribine. DewDiligence_on_SI112/1/2009
10234reuters.com Label change for TysabriArthur Radley-11/7/2009
10233From Forbes. Sounds like a big step in managing PML risk may be on the way. Hopfred hayes110/28/2009
10232<i>>Dew Diligence, my point was that risk clearly does NOT increase witDewDiligence_on_SI-10/21/2009
10231finance.yahoo.comArthur Radley-10/19/2009
10230From the abstracts published for the upcoming Society for Neuroscience meeting iBiotech Jim-10/13/2009
10229<b>FTY720 SAE’s in the FREEDOMS Study </b> <img src='http://DewDiligence_on_SI-9/30/2009
10228Dew, Thanks! This WSJ article adds a little color to the situation.. blogs.wsjArthur Radley-9/30/2009
10227Pending the release of more comprehensive safety data on both compounds, I give DewDiligence_on_SI-9/30/2009
10226Appears that Merck might be first to market.......do you have a feel for which oArthur Radley-9/30/2009
10225NVS' FTY720 is oral also.DewDiligence_on_SI-9/30/2009
10224reuters.com This Merck news will have a major impact on the MS market....havingArthur Radley-9/30/2009
10223NVS Reports Positive FTY720 FREEDOMS Data in RRMS: siliconinvestor.comDewDiligence_on_SI-9/30/2009
10222New Issue-Elan sells $625 mln in 7-yr senior notes Tue Sep 29, 2009 5:47pm EDT Qualified Opinion-9/29/2009
10221This isn't news that ELN needs....... finance.yahoo.comArthur Radley-9/29/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News